Is Immunocore Holdings plc (IMCR) a Buy, Sell, or Hold?
NASDAQ : IMCR
Immunocore Holdings plc
$34.47 USD
-$0.21 (-0.61%)
- Volume
- 42.16K
- Average Volume
- 503.66K
- Market Capitalization
- $1.75B
- P/E Ratio
- -93.18
- Dividend Yield
- 0.00%
- Price Target
- $38.00
- Year High
- $40.72
- Year Low
- $27.56
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $4.18
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Bahija Jallal |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | IMCR |
| CUSIP | 45258D105 |
| CIK | 0001671927 |
| Web | https://www.immunocore.com |
| Phone | 44 12 3543 8600 |
| Currency | USD |
| Employees | 524 |
| Country | GB |
Liquidity
| Debt-to-Equity Ratio | 1.11 |
| Payout Ratio | 0.00 |
| Current Ratio | 4.18 |
| Quick Ratio | 4.15 |
| Cash Ratio | 1.89 |
Sales & Book Value
| Annual Sales | $297.57M |
| Price / Sales | 4.60 |
| Cash Flow | -0.61 |
| Price / Cash Flow | -57.77 |
| Price / Book | 4.50 |
Price Target and Rating
| Average Stock Price Forecast | $38.00 |
| High Stock Price Forecast | $38.00 |
| Low Stock Price Forecast | $38.00 |
| Forecast Upside/Downside | -9.29% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 14 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | -$0.53 |
| Trailing P/E Ratio | -93.18 |
| PEG Ratio | 10.38 |
| P/E Growth | 10.38 |
| Net Income | -$26.42M |
| Net Margin | -4.88% |
| Pretax Margin | -2.03% |
| Return on Equity | -4.83% |
| Return on Assets | -1.76% |
Financials Score
| AltmanZ Score | 1.29 |
| Piotroski Score | 2.00 |
| Working Capital | 763.69M |
| Total Assets | 1.07B |
| Ebit | 3.1M |
| Market Cap | 1.28B |
| Total Liabilities | 678.42M |
Poll Results
About Immunocore Holdings plc (NASDAQ:IMCR) Stock
Immunocore Holdings plc, a biotechnology firm established in 1999 and based in Abingdon, United Kingdom, has reached the commercial stage in its mission to create pioneering immunotherapies. The company's development pipeline addresses a range of serious conditions, including various cancers, infectious diseases, and autoimmune disorders. Its currently marketed product, KIMMTRAK, offers a treatment option for patients with uveal melanoma that is either unresectable or has metastasized. Within oncology, Immunocore is progressing IMC-C103C through early-stage (Phase I/II) dose escalation trials for several solid tumor types, notably non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers. Another key oncology program, IMC-F106C, is also in Phase I/II dose e ... scalation studies for a diverse array of solid malignancies, including NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. For infectious diseases, the company is advancing IMC-I109V in Phase I/II clinical trials for chronic hepatitis B virus, alongside IMC-M113V, which is undergoing preclinical development for human immunodeficiency virus (HIV). Additionally, Immunocore is developing novel therapeutic candidates designed to deliver precise, targeted immunosuppression as a treatment strategy for autoimmune conditions.
Immunocore: KIMMTRAK Is Becoming A Cash Engine For A Much Larger TCR Platform
2026-06-24 08:34:39
Immunocore has transitioned from a rare-disease oncology company to a self-funded platform company with a validated commercial engine. KIMMTRAK's strong global sales, five-year survival data, and operating leverage underpin IMCR's ability to fund a broad pipeline without dilutive equity. Upcoming catalysts include pivotal readouts for tebentafusp and brenetafusp in melanoma, PRAME franchise expansion, and initial data in oncology, infectious disease, and autoimmune programs.
Is it a Good Idea to Invest in Immunocore Stock Right Now?
2026-06-17 11:01:09
IMCR is seeing strong Kimmtrak sales growth and pursuing label expansion studies that could broaden its reach across melanoma treatments.
4 Biotech Stocks Investors Should Watch in 2026
2026-06-05 11:55:27
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position LQDA, IMNM, STOK and IMCR well in this volatile sector.
2026-05-31 08:00:00
Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma Brenetafusp monotherapy resulted in a 6-month overall survival rate of 87% and disease control rate of 52% in heavily pretreated HLA-A*02:01-positive patients with melanoma Data support selection of 160 mcg dose for the ongoing Phase 3 PRISM-MEL-301 trial in first-line advanced melanoma Clinical benefit was consistent across difficult-to-treat subgroups, including patients with primary PD-1 resistance Brenetafusp was generally well tolerated as monotherapy and in combination with pembrolizumab (OXFORDSHIRE, England and RADNOR, Penn.
2026-05-31 08:00:00
Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma Brenetafusp monotherapy resulted in a 6-month overall survival rate of 87% and disease control rate of 52% in heavily pretreated HLA-A*02:01-positive patients with melanoma Data support selection of 160 mcg dose for the ongoing Phase 3 PRISM-MEL-301 trial in first-line advanced melanoma Clinical benefit was consistent across difficult-to-treat subgroups, including patients with primary PD-1 resistance Brenetafusp was generally well tolerated as monotherapy and in combination with pembrolizumab (OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md.
Wall Street Analysts Think Immunocore (IMCR) Could Surge 111.53%: Read This Before Placing a Bet
2026-05-22 10:56:03
The average of price targets set by Wall Street analysts indicates a potential upside of 111.5% in Immunocore (IMCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Immunocore reports first quarter financial results and provides a business update
2026-05-06 07:00:00
Immunocore reports first quarter financial results and provides a business update KIMMTRAK ® (tebentafusp-tebn) Q1 net sales of $106.7 million, growing by 14% year-over-year Oral presentation at AACR: KIMMTRAK doubles likelihood of being alive at five years for patients with HLA-A*02:01 positive metastatic uveal melanoma Cash, cash equivalents and marketable securities of $845 million as of March 31, 2026 (OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md.
2026-04-19 18:00:00
KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01patients with metastatic uveal melanoma OS benefit observed across key subgroups, including patients with high tumor burden, elevated LDH, and extrahepatic disease as well as those with best response of progressive disease This is the longest OS follow-up in a randomized trial in metastatic uveal melanoma and for any T cell engager in a solid tumor (OXFORDSHIRE, England and GAITHERSBURG, Md.
Frequently Asked Questions
-
What is the current Immunocore Holdings plc (IMCR) stock price?
-
Immunocore Holdings plc(NASDAQ:IMCR) stock price is $34.47 in the last trading session. During the trading session, IMCR stock reached the peak price of $40.715 while $27.555 was the lowest point it dropped to. The percentage change in IMCR stock occurred in the recent session was --0.61% while the dollar amount for the price change in IMCR stock was -$0.21.
-
IMCR's industry and sector of operation?
-
The NASDAQ listed IMCR is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of IMCR?
-
Sébastien Desprez | Vice President of Communications
Anne Achola Sefu | EVP, Chief Human Resources Officer & Director
Kripa Ram | Executive VP & Chief Operating Officer
John Goll | SVP, Finance & Chief Accounting Officer
John Trainer | SVP & Chief Operating Officer -
How many employees does IMCR have?
-
Number of IMCR employees currently stands at 524. IMCR operates from 92 Park Drive, Abingdon, OX OX14 4RY, GB.
-
Link for IMCR official website?
-
Official Website of IMCR is: https://www.immunocore.com
-
How do I contact IMCR?
-
IMCR could be contacted at phone #44 12 3543 8600 and can also be accessed through its website. IMCR operates from 92 Park Drive, Abingdon, OX OX14 4RY, GB.
-
How many shares of IMCR are traded daily?
-
The average number of IMCR shares traded daily for last 3 months was 503.66K.
-
What is the market cap of IMCR currently?
-
The market value of IMCR currently stands at $1.75B with its latest stock price at $34.47